CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Hu, Yongxian; Zhou, Yali; Zhang, Mingming; Ge, Wengang; Li, Yi; Yang, Li; Wei, Guoqing; Han, Lu; Wang, Hao; Yu, Shuhui; Chen, Yi; Wang, Yanbin; He, Xiaohong; Zhang, Xingwang; Gao, Ming; Yang, Jingjing; Li, Xiuju; Ren, Jiangtao; Huang, He

doi:10.1158/1078-0432.ccr-20-3863

Public

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Shared by NobleBlocks on Feb 24, 2021 • 12:00 AM UTC

Authors:

Yongxian Hu

Yali Zhou

Mingming Zhang

Abstract

Abstract Purpose: Autologous chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed/refractory acute lymphoblastic leukemia (r/r ALL). However, certain characteristics of autologous CAR-T cells can delay treatment availability. Relapse caused by antigen escape after ...

Discussions